Overview

A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1

Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
This study will test the safety, tolerability, and pharmacokinetics of multiple escalating doses of ISIS-DMPKRx administered subcutaneously to adult patients with DM1.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Ionis Pharmaceuticals, Inc.